SCF/KITLG/MGF (Stem Cell Factor) Drug Discovery Landscape & Assay Solutions
- By admin
- 17 Aug 2026
- Comments
Subtitle: Market Intelligence for Hematopoietic Stem Cell Mobilization, Mast Cell Disorders, and Reproductive Medicine.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCF/KITLG/MGF axis drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCF/KITLG/MGF Recombinant Protein (Soluble SCF-165, Membrane-bound SCF-220, and ECD-Fc/Mutant variants). High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed (Native Glycosylation). Sequence Verified. | View SCF Products |
| Receptor | c-KIT (CD117) ECD-Fc Fusion Protein. For binding assays and affinity characterization. Theoretical MW verified. Strictly verified by mass spec. | View c-KIT Products |
| Gene Delivery | c-KIT Lentivirus Premade Particles. Full-length ORF for stable cell line construction (Critical for flow cytometry/internalization assays). | View c-KIT Products |
| Benchmark Ab | Anti-SCF Neutralizing Antibody (Biosimilar Sequence). Recombinant positive control for receptor blocking studies and PK/PD analysis. | View SCF Products |
| Validator | SCF siRNA / c-KIT siRNA Set. For specific knockdown and assay validation (Specificity controls). | View SCF Products |
| Related Target: CSF3R | G-CSF Receptor (CD114). Synergistic pathway partner for HSC mobilization combination studies. | View CSF3R Products |
| Related Target: PDGFRA | PDGF Receptor Alpha. Off-target safety screening (RTK subfamily selectivity panel). | View PDGFRA Products |
| Related Target: FLT3LG | Synergistic cytokine for hematopoietic stem cell expansion. | View FLT3LG Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Activity | HEK293 Expressed proteins ensuring native mammalian glycosylation patterns critical for SCF stability and c-KIT binding affinity. |
| Dual Isoform Assessment (Soluble vs Membrane-bound) | Both SCF-165 (soluble) and SCF-220 (membrane-bound exon 6+) variants available with Sequence Verified purity. |
| Cross-species Preclinical Translation (Human/Cyno/Mouse) | Ortholog protein panel (Human/Mouse/Cyno) with >95% purity for comparative PK/PD and immunogenicity studies. |
| RTK Subfamily Selectivity (PDGFR Off-target) | Homolog panel including PDGFRA/B for stringent counter-screening against related receptor tyrosine kinases. |
| Ligand-Receptor Binding Quantification | c-KIT ECD-Fc fusion proteins optimized for SPR/BLI kinetics with Biotin- or Fc-tags. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks. |
Live SCF/KITLG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SCF/c-KIT axis represents a critical node in regenerative medicine and mast cell pathology. Current development focuses on next-generation stem cell mobilization agents that overcome G-CSF resistance, long-acting SCF fusion proteins for fertility applications, and selective c-KIT pathway modulators for systemic mastocytosis. As first-generation tyrosine kinase inhibitors face resistance mutations, the demand for precise ligand-based assays and mutant receptor characterization is intensifying. The race for SCF/KITLG/MGF modulators is also intensifying, with major players shifting focus from traditional systemic administration to targeted receptor antagonists and ex vivo stem cell expansion protocols. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized delivery and optimized formulations for mast cell-driven diseases and fibrotic conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Celldex, Novartis | Mastocytosis, Urticaria | Affinity Assay (Need high-purity ECD-Fc) |
| Recombinant Protein | Amgen, Sanofi | Stem Cell Mobilization | Stability Testing (Endotoxin Controlled Proteins) |
| Small Molecule | Blueprint Medicines | GIST, Systemic Mastocytosis | Selectivity Assay (Need Mutant vs WT Proteins) |